title: New pharmacological agents for the treatment of gastroesophageal reflux disease.
abstract: Proton pump inhibitors (PPIs) are currently the most effective and most widely used agents for gastroesophageal reflux disease (GERD). Despite the efficacy of these agents in healing and symptom relief, a substantial proportion of patients require twice-daily therapy with PPIs, and break-through symptoms cause others to use over-the-counter antacids and histamine 2-receptor antagonists to supplement their PPI therapy. Major strategies that are being pursued include the development of agents that have a faster onset of action for on-demand therapy; have better control of acid secretion, resulting in improved healing in advanced grades of esophagitis and better symptom control; and agents that decrease transient lower esophageal sphincter relaxations (TLESRs), thereby reducing distal acid exposure and weakly acidic refluxate. A number of new pharmaceutical agents are currently undergoing clinical evaluation for the treatment of GERD. These include agents that reduce TLESRs, serotonergic agents/ prokinetics, long-acting PPIs, mucosal protectants, and antigastrin agents. One or more of these agents may be the future of GERD therapy.
authors.affiliation: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
authors.forename: Nimish
authors.initials: N
authors.lastname: Vakil
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D020117:Cisapride / Q000627:therapeutic use; D049630:Esophageal Sphincter, Lower / Q000187:drug effects; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000008:administration & dosage; D011725:Pyridines / Q000627:therapeutic use; D011812:Quinuclidines / Q000494:pharmacology / Q000627:therapeutic use; D058828:Serotonin 5-HT4 Receptor Agonists
chemical_list: C514958:AZD0865; D000897:Anti-Ulcer Agents; D001549:Benzamides; D007093:Imidazoles; D054328:Proton Pump Inhibitors; D011725:Pyridines; D011812:Quinuclidines; D058828:Serotonin 5-HT4 Receptor Agonists; C517618:ATI 7505; D020117:Cisapride